Medicinal Chemistry Group
Our research covers a range of medicinal chemistry and chemical biology areas focused on malaria, TB and filariasis. Our approach involves a broad range of synthesis approaches, modelling and biological testing.
Much of our work is carried with collaborators in the Department of Pharmacology as well as partnerships with Liverpool School of Tropical Medicine (Professors Ward, Biagini and Taylor) and industrial partner groups including Astra Zeneca, Eisai (Boston, USA) and GSK (Tres Cantos, Madrid, Spain). More recently we have also initiated medicinal chemistry programmes in neuropathic pain and pancreatitis.
Funding and collaboration
We are extremely fortunate, and grateful, that this research is funded by research councils, charities and industry. These funds enable extremely productive collaborations with academia and industry.
- Wellcome Trust
- EPSRC (Engineering and Physical Sciences Research Council)
- MRC (Medical Research Council)
- GHIT Fund (Global Health Innovative Technology Fund)
- IVCC (Innovative Vector Control Consortium)
- Bill & Melinda Gates Foundation
- Medicines for Malaria Venture
- Sixth Framework Programme (European Union)
- Children’s Discovery Institute
- Shanghai Institute of Materia Medica
- DNDi (Drugs for Neglected Diseases initiative)
- AstraZeneca
- GSK (GlaxoSmithKline)
- Pfizer
- Bayer
- Syngenta
- Anacor
- AbbVie
- Eisai
- LSTM (Liverpool School of Tropical Medicine)
- Washington University in St. Louis
- Technische Universität Darmstadt
- Universität Tübingen (Eberhard Karls Universität Tübingen)
- King’s College London
- ChemPartner
- Wuxi AppTec
- BioFocus
